Sign in Create account
Sign in and upgrade to a paid plan to export futures history as CSV.

Aspira Pathlab & Diagnostics Limited

Healthcare · Healthcare Services

BSE: 540788
₹137.78
▼ -5.56 (-3.88%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
35/100
Weak
Valuation
—/100
Expensive
Momentum
92/100
Bullish

QVM read Momentum-led Quality Weak, Valuation Expensive, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹142 Cr
PE (TTM)
Data unavailable.
Price to Book
11.7
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
127.9
Free Cash Flow
₹1 Cr
as of March 31, 2026
Industry median ₹1 Cr (75 companies)
EPS Growth (YoY)
-108.70%
as of June 30, 2026
Industry median 13.27% (57 companies)
Net Profit Growth (TTM)
-117.70%
as of June 30, 2026
Industry median 7.21% (57 companies)
Operating Revenue Growth (TTM)
14.56%
as of June 30, 2026
Industry median 12.82% (57 companies)
Profit Growth (YoY)
-108.10%
as of June 30, 2026
Industry median 8.53% (57 companies)
Revenue Growth (YoY)
17.55%
as of June 30, 2026
Industry median 18.84% (52 companies)
Current Ratio
1.47
as of March 31, 2026
Industry median 2.06 (74 companies)
Debt to Equity
0.11
as of March 31, 2026
Industry median 0.11 (62 companies)
Interest Coverage
-0.17
as of June 30, 2026
Industry median 7.94 (57 companies)
Net Margin
-0.62%
as of June 30, 2026
Industry median 9.88% (61 companies)
Operating Margin (EBIT)
0.87%
as of June 30, 2026
Industry median 17.21% (61 companies)
Operating Margin (TTM)
-0.25%
as of June 30, 2026
Industry median 16.20% (59 companies)
Return on Assets
0.29%
as of March 31, 2026
Industry median 5.40% (58 companies)
Return on Capital Employed
2.88%
as of March 31, 2026
Industry median 10.44% (56 companies)
Return on Equity
0.44%
as of March 31, 2026
Industry median 10.16% (58 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 7 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.11)
  • No Return on equity is 15% or more (0.4%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

3 of 5 met
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-3.9%
Low 136.3700 · High 149.9900
1W return
3.5%
Low 123.4800 · High 149.9900
1M return
51.4%
Low 86.5000 · High 149.9900
52W return
125.1%
Low 86.5000 · High 149.9900
Lifetime High ₹143.3400 (Sept. 29, 2026)
Lifetime Low ₹14.1500 (Feb. 28, 2018)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
135.5
10D
128.2
20D
116.7
50D
93.3
100D
72.8
200D
47.7

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
76.4%
Month avg. delivery
86.3%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

141.38
Pivot
First resistance146.39
Second resistance155.00
Third resistance160.01
First support132.77
Second support127.76
Third support119.15
Day RSI76.3
Day MFI78.7
Day MACD14.47
Day MACD signal12.37

Beta

1M1.76
3M1.01
1Y1.01
3Y-0.45

Price change analysis

↑ 51.4%
Over 1 Month
LowHigh
86.50149.99
↑ 125.1%
Over 3 Months
LowHigh
86.50149.99
↑ 125.1%
Over 6 Months
LowHigh
86.50149.99
↑ 125.1%
Over 1 Year
LowHigh
86.50149.99
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹6 Cr
Net profit (June 30, 2026)
₹-0 Cr
Basic EPS (June 30, 2026)
₹-0.0400

Ranks #42 of 62 in Healthcare Services by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter46.58%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings increased from 18.39% to 46.58% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 60 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
21 Jul 2026 VINOD CHANDULAL MAV Bulk Buy 53,900 88.5000 BSE
21 Jul 2026 INVESTERIA FINANCIAL SERVICES PRIVATE LIMITED Bulk Sell 103,732 88.6700 BSE
17 Jul 2026 INVESTERIA FINANCIAL SERVICES PRIVATE LIMITED Bulk Sell 100,000 85.0000 BSE
9 Oct 2025 DIVYA KANDA Bulk Sell 14,721 61.9700 BSE
9 Oct 2025 DIVYA KANDA Bulk Buy 52,130 59.5600 BSE
6 Oct 2025 DEVJI DEYAT NANDA Bulk Sell 90,000 75.2600 BSE
25 Aug 2025 ADEQUATE REAL TRADE LLP Bulk Buy 72,000 58.9900 BSE
2 Jul 2024 RAJESH PREMJI BHANUSHALI Bulk Buy 68,682 28.3400 BSE
2 Jul 2024 SOCRADAMUS CAPITAL PRIVATE LIMITED . Bulk Sell 125,000 28.8500 BSE
28 Jun 2024 GLORIOUS HOLDINGS PVT LTD Bulk Sell 75,000 30.0000 BSE

All bulk and block deals →

Corporate Announcements

All 11 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 Insider Trading / SAST Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
28 Sep 2026 Insider Trading / SAST Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
25 Sep 2026 AGM/EGM Aspira Pathlab & Diagnostics Ltd - 540788 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
25 Sep 2026 AGM/EGM Aspira Pathlab & Diagnostics Ltd - 540788 - Shareholder Meeting / Postal Ballot-Outcome of AGM
16 Sep 2026 Insider Trading / SAST Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
12 Sep 2026 Board Meeting Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th September 2026
12 Sep 2026 Company Update Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement Under Regulation 30_Constitution Of Right Issue Committee
12 Sep 2026 Company Update Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Raising of Funds
12 Sep 2026 Insider Trading / SAST Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
5 Sep 2026 Insider Trading / SAST Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.11)
  • Strong revenue growth YoY (17.5%)

Weaknesses

  • Low Return on Equity (0.4%)
  • Thin net profit margin (-0.6%)
  • Declining profit YoY (-108.1%)

Opportunities

Data unavailable.

Threats

  • RSI in overbought territory (76.3)
  • Weak interest coverage (-0.2x) -- limited cushion against rising rates

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Aspira Pathlab & Diagnostics Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.